Net sales grew 32% year-over-year, but losses widened slightly as AB Sperrung invested in product development and restructured ownership. The company secured a major MedTech order and is seeking strategic partners to support future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.